Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: A 3-year prospective randomized open trial

Inflammatory Bowel Diseases

Volumn 18, Issue 9, 2012, Pages 1617-1623

  Yoshida, Koji ^a   Fukunaga, Ken ^a   Ikeuchi, Hiroki ^a   Kamikozuru, Koji ^a   Hida, Nobuyuki ^a   Ohda, Yoshio ^a   Yokoyama, Yoko ^a   Iimuro, Masaki ^a   Takeda, Naohisa ^a   Kato, Kyoichi ^a   Kikuyama, Risa ^a   Nagase, Kazuko ^a   Hori, Kazutoshi ^a   Nakamura, Shiro ^a   Miwa, Hiroto ^a   Matsumoto, Takayuki ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

anti TNF antibody; Crohn's disease; infliximab monotherapy; postoperative Crohn's disease recurrence

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB; MESALAZINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SURGERY; HUMAN; MALE; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SURVIVAL;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CHILD; COLON; CROHN DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; ILEUM; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84862647917     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21928     Document Type: Article

References (25)

1. Allison MC, Dhillon AP, Lewis WG, et al (eds). Inflammatory Bowel Disease. London: Mosby; 1998. p 15-95.
2. Hanauer SB,. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2006; 12: S3-S9.
3. Fiorino G, Rovida S, Correale C, et al. Emerging biologics in the treatment of inflammatory bowel disease: what is around the corner? Curr Drug Targets. 2010; 11: 249-260.
4. Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med. 1997; 337: 1029-1035.
5. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359: 1541-1549.
6. Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology. 2009; 136: 441-450.
7. Winship DH, Summers RW, Singleton JW, et al. National cooperative Crohn's disease study: study design and conduct of the study. Gastroenterology. 1979; 77: 829-842.
8. Myren J, Bouchier IA, Watkinson G, et al. The O.M.G.E. multinational inflammatory bowel disease survey 1976-1982. A further report on 2,657 cases. Scand J Gastroenterol Suppl. 1984; 95: 1-27.
9. de Dombel FT, Softly A,. IOIBD report no 1: observer variation in calculating indices of severity and activity in Crohn's disease. Gut. 1987; 28: 474-481.
10. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology. 1990; 99: 956-983.
11. Walters TD, Steinhart AH, Bernstein CN, et al. Validating Crohn's disease activity indices for use in assessing postoperative recurrence. Inflamm Bowel Dis. 2011; 17: 1547-1556.
12. Verma S, Kirkwood B, Brown S, et al. Oral nutritional supplementation is effective in the maintenance of remission in Crohn's disease. Dig Liver Dis. 2000; 32: 769-774.
13. Takagi S, Utsunomiya K, Kuriyama S, et al. Effectiveness of an 'half elemental diet' as maintenance therapy for Crohn's disease: a randomized-controlled trial. Aliment Pharmacol Ther. 2006; 24: 1333-1340.
14. Yamamoto T, Nakahigashi M, Umegae S, et al. Impact of long-term enteral nutrition on clinical and endoscopic recurrence after resection for Crohn's disease: a prospective, non-randomized, parallel, controlled study. Aliment Pharmacol Ther. 2007; 25: 67-72.
15. Yamomoto T, Nakahigashi M, Umegae S, et al. Prospective clinical trial: enteral nutrition during maintenance infliximab in Crohn's disease. J Gastroenterol. 2010; 45: 24-29.
16. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficiency endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002; 122: 512-530.
17. Lin MV, Blonski W, Lichtenstein GR,. What is the optimal therapy for Crohn's disease: step-up or top-down? Expert Rev Gastroenterol Hepatol. 2010; 4: 167-180.
18. Kato K, Fukunaga K, Kamikozuru K, et al. Infliximab therapy impacts on the peripheral immune-system of immunomodulator and corticosteroid naïve patients with Crohn's disease. Gut Liver. 2011; 5: 37-45.
19. Cones J, Nion-Larmurier I, Beaugerie L, et al. Impact of increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005; 54: 237-241.
20. Bennell O, Lapidus A, Hellers G,. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg. 2000; 231: 38-45.
21. Olaison G, Smedh K, Sjodahl R,. Natural course of Crohn's disease after ileocolic resection: endoscopically visualized ileal ulcers preceding symptoms. Gut. 1992; 99: 956-983.
22. Domènech E, Mañosa M, Bernal I, et al. Impact of azathioprine on the prevention of postoperative Crohn's disease recurrence: results of a prospective, observational, long-term follow-up study. Inflamm Bowel Dis. 2008; 14: 508-513.
23. Ford AC, Khan KJ, Talley NJ, et al. 5-Aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systemic review and meta-analysis. Am J Gastroenterol. 2011; 106: 413-420.
24. Reinisch W, Angelberger S, Petritsch W, et al. Azathioprine vs. mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut. 2010; 59: 752-759.
25. Cancer Warnings Required for TNF Blockers. FDA news release, The U.S. Food and Drug Administration, 4 August 2009. Available at: http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm175803.htm Accessed July 30th, 2011.